TRAb are the antibodies that switch the thyroids accelerator on, causing Graves disease. The test confirms the diagnosis without a scan and predicts both relapse after treatment and eye and pregnancy complications.
Standard range versus optimal range
| Framework | TRAb value | Source |
|---|---|---|
| Negative | below 1.75 IU/L | Common laboratory cutoff |
| Diagnostic of Graves disease | positive in about 95% of cases | ATA hyperthyroidism guideline |
| High titer concern | marked elevation raises relapse and fetal thyroid risk | ATA hyperthyroidism guideline |
When it runs high
A positive TRAb in a hyperthyroid patient essentially confirms Graves disease, sparing a radioactive uptake scan in most cases. The height of the titer carries prognostic weight, higher levels predict relapse after antithyroid drugs and can cross the placenta to stimulate a fetal thyroid.
- Graves disease, the near-exclusive cause
- Rarely transient positivity in destructive thyroiditis
When it runs low
A negative TRAb argues against Graves and points the hyperthyroidism workup toward toxic nodules or thyroiditis. Five percent of true Graves cases remain negative, so a compatible picture still earns imaging.
- No TSH receptor autoimmunity, the common finding
- Toxic nodular goiter or thyroiditis as the true cause
- Antibody levels that fell during antithyroid treatment
The antibody that holds the pedal down
The TSH receptor normally waits for pituitary orders, but TRAb mimic TSH and jam the receptor in the on position, driving the gland to overproduce hormone around the clock. Modern assays detect these antibodies in about ninety-five percent of Graves patients, turning what once required a radioactive uptake scan into a single blood tube. The same antibodies also attack tissues behind the eyes, which is why high titers travel with Graves eye disease.
A test that guides treatment length
Antithyroid drugs induce remission in roughly half of patients after twelve to eighteen months, and the end-of-treatment TRAb is the best available crystal ball. Those who finish with a negative titer relapse far less often than those still positive, a finding that shapes whether to stop, extend or move to definitive therapy with surgery or radioiodine. In pregnancy the stakes shift to the fetus, since maternal IgG crosses the placenta, and guidelines call for TRAb measurement in any mother with current or past Graves.
After the thyroid is gone
Antibodies can persist for years after surgery or radioiodine because the immune memory, not the gland, produces them. Persistently high TRAb after definitive treatment matters mainly for future pregnancies and for eye disease activity, both situations where the number still drives decisions.
Related calculators
Related biomarkers TSH · Free T4 · TPOAb